Phaseline

Targets › ITGAV

ITGAV (Integrin alpha-V): drug programs, companies and trials

8 programs from 6 companies in 12 trials: 11 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Dec 2026.

The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling. (UniProt, P06756)

Open in Phaseline: the race on ITGAV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Erasmus Medical CentercRGD-ZW800-1
RGD peptide-based fluorescent tracer targeting αvβ3 integrin
ITGAV, ITGB3Phase 2Squamous Cell Carcinoma of the LarynxMar 2028
Corbus PharmaceuticalsCRB-601
αvβ8 integrin antagonist monoclonal antibody
ITGAV, ITGB8Phase 1Solid TumorDec 2026
The First Affiliated Hospital of Xiamen University177Lu-AB-3PRGD2
Integrin αvβ3-targeting radioligand therapy (177Lu-labeled)
ITGAV, ITGB3Phase 1Refractory Solid TumorDec 2026
University of California, Davis[18F]-αvβ6-BP
Fluorine-18-labeled αvβ6 integrin-binding peptide for PET imaging
ITGAV, ITGB6Phase 1Lung CancerDec 2026
University of California, Davis[68Ga]Ga DOTA-5G
Integrin alphavbeta6 (αvβ6) targeting radioligand for PET imaging
ITGAVPhase 1Metastatic Nonsmall Cell Lung Cancer; Metastatic Lobular Breast Carcinoma; Metastatic CancerJan 2027
Memorial Sloan Kettering Cancer Center89Zr-DFO-cRGDY-PEG-Cy5-C' dots
Integrin αvβ3 targeting ultrasmall silica nanoparticle PET tracer
ITGAVPhase 1Brain CancerMar 2027
Memorial Sloan Kettering Cancer Centerfluorescent cRGDY-PEG-Cy5.5-C dots
RGD peptide-functionalized silica nanoparticles with fluorescent Cy5.5 dye for imaging int
ITGAV, ITGB3Phase 1Head and Neck MelanomaApr 2027
Peking Union Medical College Hospital68Ga-RGD
RGD peptide targeting integrin αvβ3 for PET imaging
ITGAV, ITGB3Phase 1KeloidOct 2027

Conditions

Metastatic Nonsmall Cell Lung Cancer (2) Metastatic Cancer (2) Refractory Solid Tumor (1) Solid Tumor (1) Squamous Cell Carcinoma of the Larynx (1) Metastatic Lobular Breast Carcinoma (1) Head and Neck Melanoma (1) Brain Cancer (1) Keloid (1) Lung Cancer (1)

Modalities

small molecule (7), antibody (1)

Companies

University of California, Davis (2) Memorial Sloan Kettering Cancer Center (2) The First Affiliated Hospital of Xiamen University (1) Corbus Pharmaceuticals (1) Erasmus Medical Center (1) Peking Union Medical College Hospital (1)

Related targets

ITGB3 (4) ITGB8 (1) ITGB6 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.